The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...
CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease ...
US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best strong buy stocks to invest in under $5. AbCellera Biologics Inc.
Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
FDA approved Novo Nordisk’s oral Wegovy pill for obesity and cardiovascular risk reduction, followed by a successful U.S. launch. The company announced plans to reduce its workforce by 9,000 roles as ...
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
On January 28, JoAnne Feeney, Advisors Capital Management partner and portfolio manager, appeared on CNBC’s ‘Squawk Box’ to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results